John McLoughlin
Foot Surgery · Stoughton, MANPI 1780658427
Payments from drug & device makers
What this record shows
This record is dominated by food and beverage: $502 of the $590 with a category attached, or 85.1%. 11 manufacturers reported payments, led by Smith+Nephew at 44.8% of the total. Reporting peaked in 2019 at $218 and has fallen 64.2% since, to $78 in 2025. That places this record below the midpoint for foot surgery clinicians in MA, where the typical reported total is $587.
Across 25 payments — averaging $23.58 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Smith+Nephew$264
- Organogenesis Inc.$132
- Novo Nordisk$55
- Integra Lifesciences Corporation$29
- Acell, Inc.$21
- Urgo Medical North America, LLC$19
- plus $69 from 5 others
What the payments were for
- Speaking & faculty fees$8815%
- Food & beverage$50285%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Smith+Nephew | 10 | $264 |
| Organogenesis Inc. | 4 | $132 |
| Novo Nordisk | 3 | $55 |
| Integra Lifesciences Corporation | 1 | $29 |
| Acell, Inc. | 1 | $21 |
| Urgo Medical North America, LLC | 1 | $19 |
| Convatec Inc. | 1 | $16 |
| IBSA Pharma Inc. | 1 | $15 |
| Zimmer Biomet | 1 | $14 |
| Solventum Corporation | 1 | $13 |
| Kerecis Limited | 1 | $11 |
How this compares
$590 in reported general payments places this provider in the 50th percentile of 41 foot surgery providers in Massachusetts.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| Ketoconazole | 362 | $8,894 |
| Terbinafine Hcl | 78 | $640 |
| Amoxicillin-Clavulanate PotassAmoxicillin/Potassium Clav | 12 | $230 |
| Triamcinolone Acetonide | 13 | $200 |
| Nystatin | 13 | $128 |
Paid to pharmacies, not to this prescriber.
Other foot surgery in Stoughton
- Adam LandsmanBoston$385K
- Mark RoseNatick$9K
- Jamey AllenWoburn$8K
- Ewald MendeszoonWest Roxbury$6K
- Christopher LockeBoston$6K
- Jurgen FernandezLynn$4K
- Justin OgbonnaBoston$4K
- Neil FeldmanWorcester$4K
- Wei TsengBoston$3K
- Matthew ButlerMarlborough$3K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.